Apinocaltamide
- Generic Name
- Apinocaltamide
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18F3N5O
- CAS Number
- 1838651-58-3
- Unique Ingredient Identifier
- 3Z7U1U8Z9E
- Background
Apinocaltamide is under investigation in clinical trial NCT03239691 (A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients).
Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Phase 2
Terminated
- Conditions
- Epileptic EncephalopathyContinuous Spike and Wave During Sleep
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 19
- Registration Number
- NCT05301894
- Locations
- π¬π§
Neurocrine Clinical Site, London, United Kingdom
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 31
- Registration Number
- NCT04880616
- Locations
- π³π±
Neurocrine Clinical Site, Leiden, CL, Netherlands
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Phase 2
Completed
- Conditions
- Continuous Spike and Wave During SleepEpileptic Encephalopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT04625101
- Locations
- π¬π§
Neurocrine Clinical Site, London, United Kingdom
A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04123288
- Locations
- π¨πΏ
CEPHA s.r.o., Pilsen, Czechia
Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT03165097
- Locations
- π©πͺ
Parexel, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath